α52 isn't mobile-compatible yet. It's recommended to use a desktop or laptop.
α52
Alpha 52
Where AI meets Quant
CORT
35.39
- 4.45%
Signal: -66.2
Recovering
Corcept Therapeutics Incorporated
Pharma & Biotech

News Sentiment

59m ago
Bullish 60%
Bearish 40%

News Summary

The company reported strong Q3 2025 results with revenue of $207.6 million, up 13.7% year-over-year, and net income of $19.4 million. It is highlighted as a promising growth stock by analysts and noted for its high insider ownership, which is seen as a sign of confidence. However, a key insider, the Chief Development Officer, sold 20,000 shares in early January, and an analyst at H.C. Wainwright trimmed the price target on the stock around the same time.
Home Stock Model Insights
Support expand_more